Spyre Therapeutics, Inc.SYRENASDAQ
Loading
Year-over-year SG&A expense growth
5Y CAGR
-20.2%/yr
Long-term compound
Percentile
P64
Within normal range
vs 5Y Ago
0.3x
Contraction
Streak
2 qtr
Consecutive growthStable
| Period | Value |
|---|---|
| Q4 2025 | 7.67% |
| Q3 2025 | -1.26% |
| Q2 2025 | -1.29% |
| Q1 2025 | 10.89% |
| Q4 2024 | 1.16% |
| Q3 2024 | -7.50% |
| Q2 2024 | -10.39% |
| Q1 2024 | -8.71% |
| Q4 2023 | 63.93% |
| Q3 2023 | -28.83% |
| Q2 2023 | 157.74% |
| Q1 2023 | 1.98% |
| Q4 2022 | -28.85% |
| Q3 2022 | -10.42% |
| Q2 2022 | -13.54% |
| Q1 2022 | 22.43% |
| Q4 2021 | -0.54% |
| Q3 2021 | 0.25% |
| Q2 2021 | 7.37% |
| Q1 2021 | -9.49% |
| Q4 2020 | 23.77% |
| Q3 2020 | 20.91% |
| Q2 2020 | 5.18% |
| Q1 2020 | 2.69% |
| Q4 2019 | 0.84% |
| Q3 2019 | 12.87% |
| Q2 2019 | 16.77% |
| Q1 2019 | -6.81% |
| Q4 2018 | 5.82% |
| Q3 2018 | 13.26% |
| Q2 2018 | 1.42% |
| Q1 2018 | 24.51% |
| Q4 2017 | -23.28% |
| Q3 2017 | 27.75% |
| Q2 2017 | 0.00% |
| Q1 2017 | 15.37% |
| Q4 2016 | -0.77% |
| Q3 2016 | -15.65% |
| Q2 2016 | 33.77% |
| Q1 2016 | 13.24% |